HOME >> BIOLOGY >> NEWS
AVAX Technologies' O-Vax™ cancer vaccine induces positive immunological and clinical outcomes in patients with advanced ovarian cancer

Data presented at the annual meeting of the American Society of Clinical Oncology

Kansas City, MO, May 22, 2000 -- AVAX Technologies, Inc. (NASDAQ: AVXT) today announced the presentation of data at the 36th Annual Meeting of the American Society of Clinical Oncology (ASCO) (May 20-23) in New Orleans on the company's autologous cell vaccine (AC Vaccine™) O-Vax™, for ovarian cancer. The data gathered from an ongoing Phase 1/2 trial of O-Vax in patients with advanced ovarian cancer extend earlier findings indicating that O-Vax induces a positive immunological and clinical response in ovarian cancer patients who are refractory to conventional chemotherapy. The presentation, entitled "Immunological and clinical effects of autologous, hapten-modified vaccine in patients with advanced ovarian carcinoma," offers data based on studies conducted by David Berd, M.D., Professor of Medicine, and Charles Dunton, M.D., Professor of Obstetrics and Gynecology, Thomas Jefferson University.

The extended data reflect the follow-up of 10 ovarian cancer patients with metastatic ovarian carcinoma whose tumors had progressed after failing to respond to both first and second-line chemotherapy. They were treated with seven weekly intradermal injections of O-Vax. Despite their large tumor burdens and prior chemotherapy, 8 out of 10 patients responded favorably to the vaccine, as measured by a delayed type hypersensitivity test (DTH), a skin test that measures the patient's immune response against that patient's own unmodified tumor cells. Favorable clinical responses were also observed: one patient exhibited complete regression of an abdominal mass as evidenced by a CT scan and a concomitant normalization of the CA-125 level, a protein found in the blood, which is useful for detecting and evaluating ovarian cancer. In 3 other patients, there was a transient (1-3 months duration) fall in CA-125 without radiological evidence of tumor regression. Seven o
'"/>

Contact: Sue Yeoh
syeoh@cpronline.com
201-641-2408 ext. 43
AVAX Technologies, Inc.
21-May-2000


Page: 1 2 3

Related biology news :

1. Palatin Technologies PT-141 increases sexual behavior in female animals
2. AVAX Technologies M-Vax™ cancer vaccine extends five-year overall survival in patients with lymph node metastatic melanoma
3. AVAX Technologies AC Vaccine™ improves relapse-free survival
4. AVAX Technologies M-Vax™ cancer vaccine induces T cell mediated immune reactions in patients with metastatic melanoma
5. Leader in cancer treatment and prevention research honored
6. International study findings link acne-like rash to effectiveness of new targeted cancer treatment
7. Chemical derived from vitamin-E shows early promise as cancer drug
8. New molecular link key to cellular proteins involved in cancer progression, other diseases
9. Phase II trials of second-generation antisense cancer drug planned following successful early study
10. Trial shows which brain cancer patients benefit from temozolomide
11. Genetic differences might help distinguish thyroid cancers

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/28/2020)... INDIANAPOLIS (PRWEB) , ... May 27, 2020 , ... ... of hc1 Workforce Advisor™ , a solution that uniquely combines lab testing ... to help employers systematically support the ongoing health and safety of employees returning ...
(Date:5/28/2020)... and FORT WORTH, Texas (PRWEB) , ... May ... ... stage biopharmaceutical company, announced today that interim results from their 1801 Phase 1/2 ... of Clinical Oncology (ASCO) Annual Meeting which will take place virtually on May ...
(Date:5/25/2020)... United Kingdom (PRWEB) , ... May 22, 2020 , ... ... (assay) for the detection of SARS-CoV-2, the virus that causes COVID-19. , ... to on-demand analysis of smaller sample numbers, to very large numbers of samples. ...
Breaking Biology News(10 mins):
(Date:5/21/2020)... ... 21, 2020 , ... Threats to intellectual property, political pressure ... to conventional wisdom that says the coronavirus pandemic will generally benefit biopharmaceutical companies, ... the pandemic commercially weaker, dealing with delays in new product launches and with ...
(Date:5/21/2020)... ... May 20, 2020 , ... Exo ... serve as the company’s executive vice president of product engineering and report directly ... the medical imaging space, bringing more than 24 years of technology leadership experience ...
(Date:5/15/2020)... ... 14, 2020 , ... This new service offers clients a way to speak ... quickly as the need arises. Lachman’s OnCall SMEs have extensive knowledge of a wide ... , Lachman OnCall™ SMEs are available normal business hours Monday through Friday from 9:00 ...
(Date:5/14/2020)... Calif. (PRWEB) , ... May 12, 2020 , ... ... science tools for translational research, is bringing together thousands of industry leaders, clinicians, ... scientific program highlights two plenary speakers, Carl June, MD, Director of the Center ...
Breaking Biology Technology:
Cached News: